229 related articles for article (PubMed ID: 20003335)
1. APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling.
Petty RD; Samuel LM; Murray GI; MacDonald G; O'Kelly T; Loudon M; Binnie N; Aly E; McKinlay A; Wang W; Gilbert F; Semple S; Collie-Duguid ES
BMC Cancer; 2009 Dec; 9():434. PubMed ID: 20003335
[TBL] [Abstract][Full Text] [Related]
2. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
3. Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancer.
Tan WL; Bhattacharya B; Loh M; Balasubramanian I; Akram M; Dong D; Wong L; Thakkar B; Salto-Tellez M; Soo RA; Fichtner I; Iacopetta B; Soong R
Cancer Biol Ther; 2011 Mar; 11(6):599-608. PubMed ID: 21378502
[TBL] [Abstract][Full Text] [Related]
4. Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas.
Bain GH; Collie-Duguid E; Murray GI; Gilbert FJ; Denison A; McKiddie F; Ahearn T; Fleming I; Leeds J; Phull P; Park K; Nanthakumaran S; Matula KM; Grabsch HI; Tan P; Welch A; Schweiger L; Dahle-Smith A; Urquhart G; Finegan M; Petty RD
Br J Cancer; 2014 Mar; 110(6):1525-34. PubMed ID: 24569475
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo studies on the association of long non‑coding RNAs H19 and urothelial cancer associated 1 with the susceptibility to 5‑fluorouracil in rectal cancer.
Yokoyama Y; Sakatani T; Wada R; Ishino K; Kudo M; Koizumi M; Yamada T; Yoshida H; Naito Z
Int J Oncol; 2019 Dec; 55(6):1361-1371. PubMed ID: 31638183
[TBL] [Abstract][Full Text] [Related]
6. Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy.
Phua LC; Mal M; Koh PK; Cheah PY; Chan EC; Ho HK
Cancer Chemother Pharmacol; 2013 Mar; 71(3):817-23. PubMed ID: 23271323
[TBL] [Abstract][Full Text] [Related]
7. Chromosomal imbalance maps of human 5FU-resistant colorectal cancer cell lines: implications in the analysis of 5FU-acquired resistance mechanisms.
Plasencia C; Rooney PH; Taron M; Martinez-Balibrea E; McLeod HL; Abad A
Int J Oncol; 2003 May; 22(5):945-53. PubMed ID: 12684658
[TBL] [Abstract][Full Text] [Related]
8. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
9. Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma.
Wong NA; Brett L; Stewart M; Leitch A; Longley DB; Dunlop MG; Johnston PG; Lessells AM; Jodrell DI
Br J Cancer; 2001 Dec; 85(12):1937-43. PubMed ID: 11747337
[TBL] [Abstract][Full Text] [Related]
10. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
Cushman SM; Jiang C; Hatch AJ; Shterev I; Sibley AB; Niedzwiecki D; Venook AP; Owzar K; Hurwitz HI; Nixon AB
Clin Cancer Res; 2015 Mar; 21(5):1078-86. PubMed ID: 25520391
[TBL] [Abstract][Full Text] [Related]
11. Chemosensitivity analysis and study of gene resistance on tumors and cancer stem cell isolates from patients with colorectal cancer.
Garza-Treviño EN; Martínez-Rodríguez HG; Delgado-González P; Solís-Coronado O; Ortíz-Lopez R; Soto-Domínguez A; Treviño VM; Padilla-Rivas GR; Islas-Cisneros JF; Quiroz-Reyes AG; Said-Fernández SL
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34396431
[TBL] [Abstract][Full Text] [Related]
12. HIPK2 is a potential predictive marker of a favorable response for adjuvant chemotherapy in stage II colorectal cancer.
Verdina A; Di Segni M; Amoreo CA; Sperduti I; Buglioni S; Mottolese M; Di Rocco G; Soddu S
Oncol Rep; 2021 Mar; 45(3):899-910. PubMed ID: 33650652
[TBL] [Abstract][Full Text] [Related]
13. E2F1/TS Immunophenotype and Survival of Patients with Colorectal Cancer Treated with 5FU-Based Adjuvant Therapy.
Sulzyc-Bielicka V; Domagala P; Bielicki D; Safranow K; Rogowski W; Domagala W
Pathol Oncol Res; 2016 Jul; 22(3):601-8. PubMed ID: 26831819
[TBL] [Abstract][Full Text] [Related]
14. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Cortesini C; Mazzei T; Mini E
Int J Cancer; 2011 Apr; 128(8):1935-45. PubMed ID: 20560137
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma.
Chang W; Gao X; Han Y; Du Y; Liu Q; Wang L; Tan X; Zhang Q; Liu Y; Zhu Y; Yu Y; Fan X; Zhang H; Zhou W; Wang J; Fu C; Cao G
Gut; 2014 Sep; 63(9):1457-67. PubMed ID: 24173294
[TBL] [Abstract][Full Text] [Related]
16. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
[TBL] [Abstract][Full Text] [Related]
17. New Transcriptomic Biomarkers of 5-Fluorouracil Resistance.
Fekete JT; Győrffy B
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675023
[TBL] [Abstract][Full Text] [Related]
18. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection.
Liang JT; Huang KC; Cheng YM; Hsu HC; Cheng AL; Hsu CH; Yeh KH; Wang SM; Chang KJ
Int J Cancer; 2002 Feb; 97(4):451-7. PubMed ID: 11802206
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological predictors of benefit from adjuvant chemotherapy for stage C colorectal cancer: Microsatellite unstable cases benefit.
Thomas ML; Hewett PJ; Ruszkiewicz AR; Moore JW
Asia Pac J Clin Oncol; 2015 Dec; 11(4):343-51. PubMed ID: 26471980
[TBL] [Abstract][Full Text] [Related]
20. High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab.
Kumar SS; Tomita Y; Wrin J; Bruhn M; Swalling A; Mohammed M; Price TJ; Hardingham JE
Clin Transl Oncol; 2017 Jun; 19(6):718-726. PubMed ID: 28005260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
